Related Experiment Video
Updated: May 26, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Incidence of infections in patients with giant cell arteritis: a cohort study
Madeleine Durand1, Sara L Thomas
1Centre Hospitalier de l'Universtité de Montréal, Montreal, Quebec, Canada. madeleine.durand.chum@ssss.gouv.qc.ca
Insights
Patients with giant cell arteritis (GCA) face a significantly higher risk of systemic infections, especially within six months of diagnosis. This highlights the need for safer GCA treatments.
Area of Science:
- Rheumatology
- Infectious Diseases
- Epidemiology
Background:
- Giant cell arteritis (GCA) is the most common form of vasculitis in adults.
- The infectious risk associated with GCA and its treatments is not well-established.
Purpose of the Study:
- To estimate the risk of systemic infections in patients diagnosed with GCA.
- To analyze infection risk in relation to GCA treatment, particularly focusing on steroid-sparing options.
Main Methods:
- A matched historical cohort study was conducted using The Health Improvement Research Network data.
- 1,664 GCA patients were matched with 8,078 non-GCA patients based on age, sex, general practice, and cohort entry date.
- Random-effects Poisson regression models assessed incidence rates and rate ratios for lower respiratory tract infections (LRTI), urinary tract infections (UTI), and sepsis.
Main Results:
- GCA patients had a higher incidence of systemic infections (48%) compared to non-GCA patients (37%).
- Adjusted rate ratios for LRTI, UTI, and serious infections were significantly elevated in GCA patients (1.48, 1.27, and 1.55, respectively).
- Infection risk was highest within the first six months post-GCA diagnosis and in patients younger than 75 years.
Conclusions:
- This study provides the first evidence of an increased systemic infection risk in GCA patients.
- The heightened risk is particularly pronounced in the initial months after GCA diagnosis.
- There is a critical need for novel GCA medications that enable steroid-sparing therapy to mitigate infection risk.
Objective:
Giant cell arteritis (GCA) is the most frequent form of vasculitis in adults. We sought to estimate the infectious risk associated with GCA and its treatment.
Methods:
We conducted a matched historical cohort study using data from The Health Improvement Research Network. Patients with newly diagnosed GCA were matched with up to 6 non-GCA patients by age, sex, general practice, and date of entry into the cohort. Random-effects Poisson regression models were used to obtain incidence rates and rate ratios for lower respiratory tract infections (LRTI), urinary tract infections (UTI), and sepsis, as well as for the subset of these that comprised serious infections (pneumonias, upper UTI, and sepsis). Effect modification by age, sex, and time since diagnosis of GCA was assessed.
Results:
A total of 1,664 patients with GCA were matched to 8,078 patients without GCA. Overall, 805 (48%) of the GCA patients and 3,007 (37%) of the non-GCA patients experienced ≥1 episode of systemic infection during followup, with adjusted rate ratios for LRTI, UTI, and serious infections of 1.48 (95% confidence interval [95% CI] 1.34-1.65), 1.27 (95% CI 1.10-1.46), and 1.55 (95% CI 1.22-1.96), respectively (P < 0.001 for all). The rate ratio for sepsis was 1.63 (95% CI 0.78-3.40, P = 0.20). Rate ratios for infection were highest in the first 6 months following diagnosis of GCA and in patients age <75 years, but did not vary by sex.
Conclusion:
This is the first study to show that patients with GCA are at increased risk of systemic infections, particularly in the first few months following diagnosis. New GCA medications that allow steroid sparing are needed to treat this condition.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis II: Clinical Features of Infective Endocarditis
Aneurysm II: Clinical Manifestations and Diagnostic Studies